Just listened to conference call! Good conference call, Brad covered a lot of ground. First off he admitted they started the Phase III with half the enrollment rate that they predicted but with the number of sites growing they have the enrollment rate they need to finish by the end of the year. You don't mind Brad if I don't take that to the bank.
I learned a number of new facts, first off reolysin can hide in the red blood cells and be delivered to cancer when they transfer oxygen, never heard of that before. Also the cancer that starts growing after a response does not gain an immunity from reolysin which is what I thought. He's not sure why but it's not resistance at least per Brad. Also a significant problem which you don't think of in trials was labeling in 12 languages in Europe he sounded like it was a real pain.
He also covered patents, saying a couple challenges came from big pharma and they successfully defended. The way he sounded their will be more. This is one area that could cause a negative surprise in the future, I hope not but you never know.
He also said that data from stage I will be coming in the very near future, not sure what that means but it sounds soon.
He also said that enrollment for squamous cell of the lung was slower than expected which he did not understand at all. Pancreatic is actually enrolling faster than expected. They will make a decision on new lung trial this quarter.